Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika | Zendy

Ruiyuan Cao | Zendy; Yongfen Xu | Zendy; Tianhong Zhang | Zendy; JingJing Yang | Zendy; Ye Yuan | Zendy; Pei Hao | Zendy; Yi Shi | Zendy; Jin Zhong | Zendy; Wu Zhong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika

Author(s) -

Ruiyuan Cao,

Yongfen Xu,

Tianhong Zhang,

JingJing Yang,

Ye Yuan,

Pei Hao,

Yi Shi,

Jin Zhong,

Wu Zhong

Publication year - 2017

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofx009

Subject(s) - zika virus , nitazoxanide , medicine , microcephaly , drug repositioning , drug , antiviral drug , flavivirus , approved drug , meningoencephalitis , repurposing , virology , pediatrics , pharmacology , immunology , virus , biology , ecology

Zika virus (ZIKV) infection can be the cause of congenital malformations, including microcephaly in infants and can cause other disorders such as Guillain-Barré syndrome, meningoencephalitis, and myelitis, which can also occur in some infected adults. However, at this time, there is no drug approved to treat ZIKV infection. Drug repurposing is the promptest way to obtain an effective drug during a global public health emergency such as the spread of Zika virus. In this study, we report a US Food and Drug Admistration-approved drug that is safe for pediatric use. Nitazoxanide and its bioactive metabolite, tizoxanide, have anti-ZIKV potential in vitro, and we identified that they exerts antiviral effect possibly by targeting the viral postattachment step.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research